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Background: The pathological and clinical features of invasive lobular carcinoma (ILC) differ from those of invasive
ductal carcinoma (IDC). Several studies have indicated that patients with ILC have a better prognosis than those
with ductal carcinoma. However, no previous study has considered the molecular subtypes and histological subtypes
of ILC. We compared prognosis between IDC and classical, luminal type ILC and developed prognostic factors for early
breast cancer patients with classical luminal ILC.
Methods: Four thousand one hundred ten breast cancer patients were treated at the Aichi Cancer Center Hospital
from 2003 to 2012. We identified 1,661 cases with luminal IDC and 105 cases with luminal classical ILC. We examined
baseline characteristics, clinical outcomes, and prognostic factors of luminal ILC.
Results: The prognosis of luminal ILC was significantly worse than that of luminal IDC. The rates of 5-year disease free
survival (DFS) were 91.9 % and 88.4 % for patients with luminal IDC and luminal ILC, respectively (P = 0.008). The rates
of 5-year overall survival (OS) were 97.6 % and 93.1 % for patients with luminal IDC and luminal ILC respectively
(P = 0.030). Although we analyzed prognosis according to stratification by tumor size, luminal ILC tended to
have worse DFS than luminal IDC in the large tumor group. In addition, although our analysis was performed
according to matching lymph node status, luminal ILC had a significantly worse DFS and OS than luminal IDC in
node-positive patients. Survival curves showed that the prognosis for ILC became worse than IDC over time.
Multivariate analysis showed that ILC was an important factor related to higher risk of recurrence of luminal
type breast cancer, even when tumor size, lymph node status and histological grade were considered.
Conclusions: Luminal ILC had worse outcomes than luminal IDC. Consequently, different treatment approaches
should be used for luminal ILC than for luminal IDC.
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Invasive lobular carcinoma (ILC) constitutes 5 % or less
of the cases of breast carcinoma in most series [1]. How-
ever, the frequency of ILC has been reported to be as
high as 10–14 % of invasive carcinomas according to less
restrictive diagnostic criteria [1]. The pathological and
clinical features of ILC differ from those of invasive* Correspondence: hiwata@aichi-cc.jp
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vival of patients with ILC is higher than patients with
IDC [1]. The typical pathological feature of ILC are lack
of cohesion among tumor cells and the presence of slen-
der strands of cells arranged in a linear fashion [1, 5].
Further, ILC can be discriminated between classical
and pleomorphic forms. Classical ILC consists of small,
uniform cells with round nuclei and inconspicuous
nucleoli. Pleomorphic ILC consists of cells larger thanis distributed under the terms of the Creative Commons Attribution 4.0
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philic cytoplasm. Classical ILC has a more favorable
prognosis than the pleomorphic form [4].
In invasive ductal carcinoma, the prognosis differs
widely according to molecular subtype. Unfortunately,
there is no evidence of any difference in prognosis
between ILC and IDC with similar molecular sub-
types. The aims of this study were to compare prog-
nosis between IDC and ILC of the luminal type and
to develop prognostic factors for early breast cancer
patients with classical ILC.Methods
Study population
Four thousand one hundred ten breast cancer patients
underwent surgery at the Aichi Cancer Center Hospital
from 2003 to 2012. We obtained the clinical and patho-
logical data from patient’s records retrospectively. The
diagnosis of ILC was defined by a typical appearance of
microscopic pathological features and immunohistochemi-
cal staining of E-Cadherin. Variants of ILC were excluded.
Patients for whom information on estrogen receptor
(ER), progesterone receptor (PgR) and human growth
factor receptor 2 (HER2) status was unavailable were
excluded from this study. Furthermore, patients with
cT4 breast cancer, metastasis at presentation, bilateral
breast cancer, a history of other cancer, or neo adjuvant
therapy were also excluded.
Our study was approved by the Institutional Review
Board of Aichi Cancer Center Hospital. Informed
consent was obtained from each patient in oral and
written form before inclusion in the study.Pathological assessment and definition of molecular
subtypes
Histopathological diagnoses of ILC and IDC using
hematoxylin–eosin staining were made by several
pathologists at Aichi Cancer Center Hospital. Hormone
receptor (ER and PgR) status was determined by immu-
nohistochemical staining. Hormone receptor-positive
status was defined as a score of equal or greater than 3
of ER on the Allred Score [6]. HER2 positive was defined
as a Herceptest-score of 3+ or fluorescent in situ
hybridization (FISH) positive following a Herceptest-
score of 2 + [7]. The definition of luminal type was deter-
mined as ER positive and HER2 negative. Histological
grading was performed using the Nottingham histo-
logical grading system. Tumor stage was stratified ac-
cording to the AJCC 7th edition TNM staging system
for breast cancer. The dataset supporting the conclu-
sions of this article is included within the article and its
additional file (Additional file 1).Statistical analysis
Differences in clinicopathological features between IDC
and ILC were compared using chi-squared analysis and
Fisher’s test. The log-rank test and estimation of hazard
ratios using COX regression analysis were used for uni-
variate analysis, and cumulative survival curves were
derived by Kaplan-Meier methods. Disease free survival
(DFS) was defined as the time from the date of operation
to relapse including local recurrence, or death. Overall
survival (OS) was defined as the time from the date of
operation to death from any cause. Cox regression ana-
lysis using proportional hazards modeling was used in
multivariate analyses. The proportional hazards assump-
tion was verified using the Schoenfeld Residuals Test.
All tests were two-sided, and a P value of <0.05 was con-
sidered statistically significant. All data were analyzed
using STATA software version12.0.
Results
Patient and tumor characteristics
We identified 1,998 cases of IDC and 115 cases of ILC
after excluding patients according to the criteria de-
scribed above as well as cases of carcinoma in situ.
Among these, the number of cases of IDC and ILC with
luminal subtype were 1,661(83 % of IDC) and 104(90 %
of ILC), respectively. Among ILC, 3 % were hormone re-
ceptor positive and HER2 positive and 2 % were hor-
mone receptor negative and HER2 positive, and 5 %
were triple negative. The median follow-up time was
64 months (0–126). The clinical and pathological tumor
characteristics of luminal IDC and luminal ILC are
shown in Table 1. The tumor size of luminal ILC was
larger than that of luminal IDC (P = 0.002). Luminal ILC
was more likely to have a lower histological grade than
luminal IDC (P < 0.001).
Positive margins were more frequently found in lu-
minal ILC than in luminal IDC (P = 0.016). The majority
of patients with luminal ILC were treated with adjuvant
hormonal therapy. In addition, those with luminal ILC
were more likely to receive adjuvant hormonal therapy
than those with luminal IDC (P = 0.008). However, there
were no significant differences in other characteristics
(age, menopausal status, lymph node status and chemo-
therapy) between the two groups.
Univariate analysis of luminal type
The prognosis of luminal ILC was significantly worse
than that of luminal IDC. The 5-year DFS was 91.9 %
and 88.4 % for patients with luminal IDC and luminal
ILC, respectively (P = 0.008), while the 5-year OS was
97.6 % and 93.1 %, respectively, for patients with luminal
IDC and luminal ILC (P = 0.030) (Fig. 1).
The survival curves for luminal IDC and luminal ILC
after stratification by tumor size are shown in Fig. 2.
Table 1 Patient characteristics
Luminal IDC (n = 1661) Luminal ILC (n = 104) (n = 104)
n % n % P-value
Median follow-up time(months) 53 49.5
Age(years)
Median 53 53
< 50 678 40 44 42
≧50 982 59 60 57 0.768
Menopause status
Pre 812 48 52 50
Post 844 50 50 48 0.703
Histological grade
1 486 29 68 65
2 875 52 26 25
3 248 14 2 1 <0.001
Tumor size
T1 1174 70 57 54
T2 422 25 40 38
T3 63 3 7 6 0.002
ER(Allred score)
3 19 1 0 0
4 31 2 0 0
5 30 2 1 1
6 62 4 5 5
7 246 15 15 14
8 1273 76 83 80 0.575
HER2 status
0 439 26 25 24
1 995 60 67 64
2(FISH-) 227 14 12 12 0.682
Lymph node status
Positive 489 29 34 32
Negative 1021 61 61 58 0.492
Initial surgical treatment
BCS 779 47 41 39
Mastectomy 882 53 63 61 0.007
Positive margins 38 2.2 7 6.7 0.016
Endocrine therapy
Yes 1424 85 99 95
No 231 13 5 4 0.008
Chemotherapy
Yes 672 40 44 42
No 982 59 60 57 0.735
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, FISH fluorescent in situ hybridization, BCS breast conserving surgery
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Fig. 1 Patient outcomes of luminal IDC and luminal ILC; (a) disease-free survival (b) overall survival, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma
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the two groups (Fig. 2) However, the 5-year DFS of lu-
minal ILC tended to be worse than that of luminal IDC
in cases with large tumors (T3 cases) (26.7 % vs 74.9 %,
P = 0.07) (Fig. 2c). The survival curves for luminal IDC
and luminal ILC after stratification by lymph node status
are shown in Fig. 3. There were no significant differ-
ences in DFS between the two groups in the node nega-
tive population (Fig. 3a). However, the 5-year DFS of
luminal ILC was significantly worse than that of luminal
IDC in the node positive population (77.4 % vs 85.5 %,
P = 0.02) (Fig. 3b). Furthermore, the 5-year OS of
luminal ILC was also significantly worse than that of
luminal IDC in the node-positive population (83.3 % vs
94.4 %, P = 0.017) (Fig. 3c).
In univariate analysis, ILC (P = 0.008), large tumor
size (P < 0.001), lymph node positivity (P < 0.001),
and high grade (P < 0.001) were worse prognostic
factors for luminal type breast cancer (Table 2). The
test of non-proportional hazards for DFS for the
variable ‘pathology type’, using the Schoenfeld Resid-
uals Test, was insignificant. Time split analysis and
graphical results suggested the presence of an associ-
ation between pathology type and DFS over time
(Table 3, Fig. 4).Multivariate analysis of luminal type
Multivariate analysis was performed using Cox regres-
sion models to determine the independent prognostic
factors of luminal type breast cancer. Factors in this
analysis were pathological type (IDC or ILC), age,
tumor size, lymph node status, histological grade,
endocrine therapy, and chemotherapy. Pathological
type, tumor size, lymph node status, histological
grade, and endocrine therapy were prognostic factors
independently associated with recurrence of luminal
type breast cancer (Table 4). Moreover, tumor size
and lymph node status were the prognostic factors
for better survival in luminal type breast cancer.Univariate analysis and multivariate analysis in luminal
ILC
In univariate analysis, large tumor size (P < 0.001) and
lymph node positivity (P = 0.015) correlated with signifi-
cantly worse DFS in luminal ILC (Table 4). When tumor
size and lymph node status were entered in a multivari-
ate analysis for luminal ILC recurrence, large size was an
independent prognostic factor (P = 0.024) (Table 5).
Discussion
ILC is the second most common type of invasive breast
cancer. The clinical and biological characteristics of ILC
differ from those of IDC [2–4]. Several studies have indi-
cated that patients with ILC have a better prognosis than
patients with ductal carcinoma. Currently, breast cancer
can be classified into four molecular subtypes (luminal A,
luminal B, HER2-positive, or triple negative) based on
their expression of hormone receptors, HER2, and Ki-67.
The subtypes of luminal, HER2-positive, and triple nega-
tive in this study are defined as ER positive and HER2
positive or negative, ER negative and HER2 positive, ER
negative and HER2 negative, respectively [8–10]. Al-
though there are many reports that these molecular sub-
types are strongly associated with prognosis in IDC [8, 9],
there are few reports of any association in ILC. Iorfida et
al. showed that each molecular subtype had different out-
comes in ILC, as they do in IDC [4]. They reported that
ILC was more likely to be associated with luminal type
than IDC, while luminal A had higher rates of DFS and
OS than other molecular subtypes of ILC. However, they
did not compare prognosis between IDC and ILC strati-
fied into molecular subtypes.
Moreover, ILC is classified into histological subtypes
(classical, alveolar, solid, tubulolobular, pleomorphic, and
mixed type). Each histological subtype has a different
prognosis [1, 5]. Among them, pleomorphic ILC has a
worse prognosis than classical ILC [4]. However, there
has been no previous study in which molecular subtypes
and histological subtypes of ILC were considered. There-
fore, we performed a retrospective analysis to compare
Fig. 2 Patient outcomes of luminal IDC and luminal ILC stratified
according to tumor size; (a) T1 (b) T2 (c) T3, IDC invasive ductal
carcinoma, ILC invasive lobular carcinoma
Fig. 3 Patient outcomes of luminal IDC and luminal ILC stratified
according to lymph node status; (a) disease free survival in lymph
node-negative patients (b) disease free survival in lymph node-positive
patients (c) overall survival in lymph node-positive patients, IDC inva-
sive ductal carcinoma, ILC invasive lobular carcinoma
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ILC.
In this study, luminal ILC patients had larger tumors than
luminal IDC patients. Moreover, luminal ILC tumors were
of a lower grade than luminal IDC tumors. The characteris-
tics of these patients tended to be similar to those previ-
ously reported for all types of ILC [2, 4, 11–15]. The larger
size of ILC can be attributed to the biological behavior of
ILC. Their indolent infiltration into stroma without adesmoplastic reaction could make it difficult to detect small
ILC on radiological examination [11, 12]. Although previ-
ous studies have shown that the rate of lymph node positiv-
ity is higher in ILC [3, 12, 15], there was no difference in
lymph node metastasis between the two groups in this
study. We believe that this may have been due to the exclu-
sion of pleomorphic ILC with aggressive clinical features.
Table 2 Univariate analysis for luminal types (ILC and IDC)
DFS OS
Variables HR (95 % CI) P-value HR (95 % CI) P-value
Age
≧50 1.0 1.0
< 50 1.14(0.80–1.64) 0.455 1.17(0.65–2.11) 0.591
Menopause status
Post 1.0 1.0
Pre 1.06(0.75–1.51) 0.708 1.20(0.68–2.11) 0.513
Tumor size
< 2 1.0 1.0
2≤ T < 5 3.82(2.62–5.58) 6.08(3.19–11.57)
5≥ 8.24(4.72–14.39) <0.001 11.81(4.74–29.42) <0.001
Lymph node status
Negative 1.0 1.0
Positive 3.51(2.40–5.12) <0.001 6.26(3.17–12.36) <0.001
Pathology type(ILC,IDC)
IDC 1.0 1.0




3 4.41(2.53–7.70) <0.001 5.52(2.15–14.12) <0.001
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DFS disease free survival, OS overall survival, HR hazard ratio, 95 % CI 95 % confidence interval
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ceived hormone therapy was significantly lower than
those with luminal ILC in this study. We consider that
the reason for this difference may be as follows. There
was a significant difference in tumor size between lu-
minal IDC and luminal ILC. Luminal IDC patients who
did not receive hormone therapy had very small tumors
(mainly less than 10 mm).
In our study, the prognosis of luminal ILC was signifi-
cantly worse than that of luminal IDC. Although we an-
alyzed prognosis according to stratification by tumor
size, luminal ILC tended to have worse DFS than
luminal IDC in the large tumor group. In addition,Table 3 Univariate analysis for luminal types (ILC and IDC, analysis o
0–5 years of follow-up







IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DFS disease free survalthough our analysis was performed according to
matching lymph node status, luminal ILC had a signifi-
cantly worse DFS and OS than luminal IDC in node-
positive patients. DiCostanzo et al. compared IDC and
classical ILC, matched for age, tumor size and nodal sta-
tus [16]. They showed that classical ILC had better DFS
than IDC. The difference between our results and theirs
might be accounted for by the fact that they did not con-
sider molecular subtypes. The large study by Wasif et al.
also reported that stage-matched prognosis was better
for ILC than IDC [3]. They reported that ILC was more
often ER positive and suggested that the favorable prog-
nosis of ILC might be related to high expression of ER.f the split times)
5 years to end of follow-up





ival, OS overall survival, HR hazard ratio, 95 % CI 95 % confidence interval
Fig. 4 Assessment of the nature of non-proportional hazards when patients’ with ILC are opposed to IDC using the Schoenfeld Residuals Test; ILC
invasive lobular carcinoma, IDC invasive ductal carcinoma, DFS disease free survival, OS overall survival
Table 4 Multivariate analysis for luminal types (IDC, ILC)
DFS OS
Variables HR (95 % CI) P-value HR (95 % CI) P-value
Age
≧50 1.0 1.0
< 50 1.32(0.88–1.99) 0.176 1.60(0.79–3.25) 0.184
Tumor size
< 2 1.0 1.0
2≤ T < 5 2.35(1.49–3.71) 3.85(1.79–8.26)
5≥ 4.04(2.11–7.73) <0.001 5.84(1.65–14.15) <0.001
Lymph node status
Negative 1.0 1.0
Positive 2.28(1.37–3.79) 0.001 3.06(1.39–8.15) 0.010
Pathology type
IDC 1.0 1.0




3 2.31(1.22–4.38) 0.009 2.44(0.87–6.81) 0.060
Endocrine therapy
No 1.0 1.0
Yes 0.40(0.25–0.70) 0.002 0.35(0.15–0.82) 0.017
Chemotherapy
No 1.0 1.0
Yes 1.29(0.74–2.25) 0.320 1.02(0.42–2.50) 0.745
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma DFS disease free
survival, OS overall survival, HR hazard ratio, 95%CI 95 % confidence interval
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was an important factor related to higher risk of recur-
rence of luminal type breast cancer, even when tumor
size, lymph node status and histological grade were con-
sidered. Tubiana-Hulin et al. reported that pathological
type (IDC/ILC) was not related to DFS or OS in their
multivariate analysis [15]. However, their study was not
limited to luminal type breast cancer. To date, this study
is the first attempt to compare the prognosis of luminal
IDC and luminal ILC. In addition, this study indicates
that ILC is an important prognostic factor for luminal
type breast cancer.
In our study, the most important prognostic factor for
luminal ILC was tumor size. This result was basically the
same as that reported from previous studies, such as the
finding that tumor size and lymph node status were prog-
nostic factors for ILC, as reported for IDC [3, 4, 13, 16].
The results of our study might be related to responsive-
ness to adjuvant therapies. In advanced cases such as
those with large tumors or which are lymph node-
positive, adjuvant chemotherapy was generally performed.
In fact, in this study, most T3 and lymph node-positive
patients were administered adjuvant chemotherapy (lu-
minal ILC: 85 % of T3, 97 % of LN+, luminal LDC: 87 %
of T3, 80 % of LN+). However, the response of ILC to pri-
mary chemotherapy was significantly lower than that of
IDC reported in a previous study [14, 15, 17]. Therefore,
in advanced cases that usually receive adjuvant chemo-
therapy, patients with luminal ILC might show worse
prognosis than those with luminal IDC. Regarding hor-
mone therapy, a previous study reported that poorer DFS
was observed for ILC patients with endocrine-responsive
tumors who did not receive any adjuvant hormonal
therapy [12, 15], and hormonal therapy might be consid-
ered to improve the outcome. There have been several
large studies which reported that the prognosis for ILC
Table 5 Univariate analysis and multivariate analysis for





























ILC invasive lobular carcinoma, DFS disease free survival, HR hazard ratio, 95 % CI
95 % confidence interval
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patterns were observed in our results. A time dependent as-
sociation between pathology type and DFS was observed.
We found an increased hazard for DFS among patients
with ILC. These results imply that ILC exhibits indolent
but progressive clinical behavior. This might also be an im-
portant factor when considering the treatment options for
ILC. Some authors have considered that extended adjuvant
hormone therapy might be necessary for luminal ILC [4].
Several studies have shown that the metastatic patterns of
ILC differ from those of IDC [12, 13]. Although we did not
take into consideration the site and timing of metastasis in
this study, this difference might also be related to the worse
prognosis of ILC. Moreover, there were more cases with
positive margins in luminal ILC than in luminal IDC in this
study. It could be due to indistinct margins of ILC inimaging study and therefore, related to higher likelihood of
local recurrences in luminal ILC than in luminal IDC.
One limitation of this study is that our results were
based on a retrospective analysis. HER2 status could be
inconsistent during the study period due to several
changes of the definition of HER2 positivity [7]. More-
over, sufficient data of PgR and Ki-67 required to distin-
guish between luminal A and luminal B were not
available, therefore we defined luminal type as ER posi-
tive and HER2 negative in this study and we could not
discuss about a difference between luminal A ILC and
luminal B ILC. However, Engtrom et al. reported that
ILC had worse prognosis than IDC for both luminal A
and luminal B. Additionally, they showed that luminal A
ILC and luminal B ILC had similar prognosis [18]. Even
though we used different definitions of ‘luminal’, we had
same finding that luminal ILC had worse prognosis than
luminal IDC. This might mean that PgR and Ki-67 are
not associated with the prognosis of luminal ILC.
Despite some limitations, this is the first study which
suggests that ILC is an independent prognostic factor
for luminal type breast cancer, and the results suggest
that it may be necessary to reconsider the clinical ap-
proach for luminal ILC. In order to examine this hy-
pothesis, several gene-expression profiling studies will be
required to determine whether ILC has different pat-
terns of gene expression from IDC even if histological
grade and molecular subtypes are matched [19]. There-
fore, other scientific approaches such as gene-expression
profiling studies may provide answers to the questions
raised about clinical behavior and systemic approaches
to ILC.
Conclusions
In conclusion, luminal ILC was associated with worse
outcomes than luminal IDC. Consequently, luminal ILC
should be approached with a different adjuvant therapy
from luminal IDC, and a prospective clinical trial of ad-
juvant therapies for luminal ILC is required. Other ap-
proaches such as genomics are also essential to answer
the question of clinical behavior and to identify appro-
priate therapies for ILC.
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